Clinical Progress Photolitec is advancing two oncology programs, PHOTOBAC and PETONCO, toward Phase I clinical trials with an ODD and FDA IND for glioblastoma, signaling regulatory readiness and potential for licensing, co-development, or milestone-driven partnerships with pharma and CROs.

See and Treat The company develops photosensitizing compounds designed for cancer imaging and therapy using PDT and SDT, presenting opportunities to partner with imaging hardware vendors, diagnostic platforms, and cancer centers seeking integrated see-and-treat solutions.

Deep Imaging Advantage Long-wavelength-absorbing compounds aim to image and treat deeply seated tumors, offering sales angles to suppliers of surgical and radiology imaging systems and to hospitals performing challenging tumor resections.

Early Stage Assets With pre-revenue status (revenue 0-1M), Photolitec can pursue licensing, co-development, or CRO partnerships to monetize its oncology imaging and PDT/SDT assets through collaborative trials and manufacturing support.

Local Bio Network Located in Buffalo's Bio-Cluster and lab facilities at 73 High Street, the company can leverage regional academic medical centers, grant programs, and local partnerships to accelerate trials and create channel partners for imaging agents and therapeutics.